Better margins despite cautious sales growth
Better profits achieved across 3 business lines
Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines
–Better-than-feared 3Q results
No, Reviving the Robinson-Patman Act Will Not Lead to More Competition or a Better Economy
Better 2H23 and FY24 as Mexico to turn profitable
Better Demand Planning: How Finance Can Lead Its Successful Transformation
Still better positioned than most rivals
FY22 net margins better than expected
FY22 results below; GPM recovery on better product mix